Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lenalidomide

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

- PMLiVE

Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

Trial pause follows reports of three cases of peripheral neuropathy in phase 1 study

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

- PMLiVE

Takeda and KSQ Therapeutics to develop immune-based cancer treatments

Collaboration will utilise KSQ’s CRISPR-screening technology

Effects of the Pandemic on Evidence Generation & Scientific Exchange

Farah Husein, Director, Evidence Generation, Canadian Centre of Excellence, at Takeda, discusses all things evidence generation, including the impact of the COVID-19 pandemic on HEOR, RWE, epidemiology, and PRO studies and...

Impetus Digital

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

Takeda to sell Japan consumer health unit for $2.3bn

Deal helps to reduce debt accrued from Shire takeover

- PMLiVE

Janssen scores another expansion for new Darzalex combination in the US

Myeloma med approved in combination with Amgen's Kyprolis

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

Gut instincts lead Takeda to GI pipeline success

Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy

If our patients are diverse, why are clinical trials so white?

Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links